CHMP recommends label expansion for Ozurdex

The EMA's Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion recommending approval for the use of Allergan's (AGN) Ozurdex (dexamethasone 700 mcg intravitreal implant in applicator) as a treatment for vision loss in patients with diabetic macular edema who have an artificial lens implant and who do are responding sufficiently to or are unsuitable for non-corticosteroid therapy.

Ozurdex's current labeling in Europe covers macular edema in patients with retinal vein occlusion and inflammation of the posterior segment of the eye characterized as non-infectious uveitis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs